NCT00908232 · MORE INFO

Limitations, agreements, and source contact

Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD · Source last updated 2015-01-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee: false
restriction Type: GT60
restrictive Agreement: true

limitations And Caveats

description: The response rate of bortezomib in combination with dexamethasone after 4 cycles was much higher than originally assumed. Therefore the sample size of the randomized groups is too small for further statistical analysis.

point Of Contact

organization: Janssen-Cilag Germany
phone: +49 2137 955-492
title: EMEA Medical Affairs Director Oncology

Complete source fields

certain Agreement

pi Sponsor Employee: false
restriction Type: GT60
restrictive Agreement: true

limitations And Caveats

description: The response rate of bortezomib in combination with dexamethasone after 4 cycles was much higher than originally assumed. Therefore the sample size of the randomized groups is too small for further statistical analysis.

point Of Contact

organization: Janssen-Cilag Germany
phone: +49 2137 955-492
title: EMEA Medical Affairs Director Oncology

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice